ROCKVILLE, Md., Sept. 29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company, announced today that Mr. Frederick Driscoll, Chief Financial Officer of Novavax, will be presenting at the BIO Investor Forum. The presentation will take place on Wednesday, October 6, 2010 at 1:00pm PT at the Palace Hotel, San Francisco, California. Mr. Driscoll will provide a company overview, outline its competitive position and characterize Novavax’s outlook.
About Novavax
Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company’s website: www.novavax.com.
SOURCE Novavax, Inc.
